-+ 0.00%
-+ 0.00%
-+ 0.00%

AC Immune Doses First Participant In Phase 1 Study Of ACI-19764 Targeting Neuroinflammation In Alzheimer's, Parkinson's And ALS

Benzinga·02/24/2026 12:18:03
Listen to the news
  • ACI-19764 is an orally available highly brain-penetrant small molecule NLRP3 inhibitor
  • NLRP3 inhibitors are a major new class of compounds linked to a broad spectrum of inflammatory conditions including both metabolic and neurological diseases
  • ACI-19764 is an important addition to AC Immune's growing small molecule pipeline
  • Phase 1 results in healthy volunteers are expected in H2 2026